Jan Paul de Boer

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

L. van der Molen, A. Al-Mamgani, L. Devriese, 2024, Head & neck.

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

R. de Bree, M. Hendriks, C. V. van Gils, 2023, PloS one.